Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-323, Enanta’s L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).
https://finance.yahoo.com/news/enanta-pharmaceuticals-receives-fda-fast-110000666.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.